NightHawk Biosciences Confirms NYSE American Listing Details

TL;DR

**NHWK filed a routine 8-K confirming its NYSE American stock listing, no new news.**

AI Summary

NightHawk Biosciences, Inc. (NHWK) filed an 8-K on January 16, 2024, to update its registration information, specifically noting its Common Stock, $0.0002 par value per share, is registered on the NYSE American LLC under the trading symbol NHWK. This filing is a routine update, indicating no major operational or financial changes. For investors, this simply confirms the current listing details and doesn't present new information that would significantly impact investment decisions, but it's important for maintaining transparency and compliance.

Why It Matters

This filing is a routine administrative update, confirming NightHawk Biosciences' stock listing on the NYSE American LLC. It doesn't signal any new business developments or financial changes, but ensures regulatory compliance and transparency for investors.

Risk Assessment

Risk Level: low — This filing is purely administrative and does not introduce any new financial or operational risks to the company.

Analyst Insight

This filing is purely administrative and does not provide new information that would warrant an immediate investment action. Investors should continue to monitor for filings related to financial performance, strategic developments, or operational changes.

Key Numbers

• $0.0002 — par value per share (the stated par value of NightHawk Biosciences' common stock)

Key Players & Entities

• NightHawk Biosciences, Inc. (company) — the registrant filing the 8-K
• NHWK (company) — the trading symbol for NightHawk Biosciences, Inc.
• NYSE American LLC (company) — the exchange where NightHawk Biosciences' common stock is registered
• $0.0002 (dollar_amount) — par value per share of common stock
• January 16, 2024 (date) — date of earliest event reported and filing date

FAQ

Key Financial Figures

• $0.0002 — nge on which registered Common Stock, $0.0002 par value per share NHWK NYSE America
• $20 million — ufacturing contracts (representing over $20 million in potential revenue) with customers th

Filing Documents

• nhwk_8k.htm (8-K) — 29KB
• ex99z1.htm (EX-99.1) — 30KB
• image_033.jpg (GRAPHIC) — 30KB
• image_034.jpg (GRAPHIC) — 82KB
• image_035.jpg (GRAPHIC) — 39KB
• image_036.jpg (GRAPHIC) — 50KB
• image_037.jpg (GRAPHIC) — 44KB
• image_038.jpg (GRAPHIC) — 66KB
• image_039.jpg (GRAPHIC) — 55KB
• image_040.jpg (GRAPHIC) — 37KB
• image_041.jpg (GRAPHIC) — 53KB
• image_042.jpg (GRAPHIC) — 36KB
• image_043.jpg (GRAPHIC) — 44KB
• image_044.jpg (GRAPHIC) — 34KB
• image_045.jpg (GRAPHIC) — 43KB
• image_046.jpg (GRAPHIC) — 41KB
• image_047.jpg (GRAPHIC) — 57KB
• image_048.jpg (GRAPHIC) — 40KB
• 0001079973-24-000065.txt ( ) — 1315KB
• nhwk-20240116.xsd (EX-101.SCH) — 3KB
• nhwk-20240116_def.xml (EX-101.DEF) — 26KB
• nhwk-20240116_lab.xml (EX-101.LAB) — 36KB
• nhwk-20240116_pre.xml (EX-101.PRE) — 25KB
• nhwk_8k_htm.xml (XML) — 5KB

01. Regulation

Item 7.01. Regulation FD Disclosure. NightHawk Biosciences, Inc. (the "Company") will be making several presentations to investors over the next several weeks. In connection with the presentations, the Company intends to discuss the investor presentation, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and in the investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

01 Other Items

Item 8.01 Other Items On January 16, 2024, the Company updated its corporate presentation. The updated presentation highlights the Company's focus on its contract development and manufacturing organization ("CDMO") business, which is operated by the Company's subsidiary, Scorpius Biomanfacturing, Inc. ("Scorpius"). Since inception, Scorpius has signed 12+ development and manufacturing contracts (representing over $20 million in potential revenue) with customers that include premier biopharma and emerging biotech companies.

01 Financial Statements and

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Corporate Presentation dated January 2024 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 16, 2024 NightHawk Biosciences, Inc. By: /s/ Jeff Wolf Name: Jeff Wolf Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR